

# Primary Bladder Amyloidosis Mimicking Bladder Cancer: A Rare Case Report

Can Sinirsiz<sup>1</sup>, Volkan Şen<sup>1</sup>, Emine Burçin Tuna<sup>2</sup>, Ozan Bozkurt<sup>1</sup>

<sup>1</sup>Dokuz Eylül University Faculty of Medicine, Department of Urology, İzmir, Türkiye

<sup>2</sup>Dokuz Eylül University Faculty of Medicine, Department of Medical Pathology, İzmir, Türkiye

## Abstract

Bladder amyloidosis is a rare condition that can mimic malignancy clinically and radiologically. A 44-year-old female patient was admitted to our clinic with macroscopic hematuria and dysuria. A 2-cm nodular lesion was detected next to the left ureteral orifice in the bladder on abdominal ultrasound. The lesions were excised via transurethral resection. Pathological examination revealed amyloidosis. After internal medicine evaluation, the patient was diagnosed with primary bladder amyloidosis, and it was decided to follow-up the patient with cystoscopy.

**Keywords:** Amyloidosis, bladder amyloidosis, bladder cancer, endoscopy, pathology

## Introduction

Amyloidosis is a disease caused by the accumulation of amorphous proteins in many organs and tissues in the extracellular space. It is divided into two groups; primary and secondary amyloidosis. Primary amyloidosis is a systemic disease that can affect multiple organs and is caused by plasma cell dyscrasia (1). Although bladder amyloidosis is very rare, it can mimic bladder malignancy clinically and radiologically (2). Clinically, it can present with symptoms such as gross painless hematuria, microscopic hematuria, dysuria, and irritative voiding symptoms. A definitive diagnosis is made by histopathological examination of tissues that show Congo red staining and apple green fluorescence. We present a case of bladder amyloidosis, which is rarely reported in the literature.

## Case Presentation

A 44-year-old female patient was admitted to our clinic with macroscopic hematuria and dysuria. The urine culture was sterile, and red blood cell 17/(HPF), leukocyte esterase (-), and protein (-) in urine test. The hemogram, kidney, and liver function tests were all within normal limits. A 2-cm nodular lesion was detected next to the left ureteral orifice in the bladder on abdominal ultrasound. Computed tomography (CT) urography revealed two nodular lesions measuring 9 and 4 mm next to the left ureteral

orifice (Figure 1). A diagnostic cystoscopy was performed; two nodular bullous lesions measuring 15 mm and 5 mm next to the left ureteral orifice were removed via transurethral resection (TUR). Pathological examination revealed amyloidosis (Figure 2). The patient was consulted by the internal medicine and nephrology departments, and systemic amyloidosis was not considered. The patient was diagnosed with primary bladder amyloidosis, and it was decided to follow-up the patient with cystoscopy. Recurrence was detected during the first year of cystoscopy, and the pathological result revealed the presence of amyloidosis. The patient is currently followed up with annual cystoscopy. An informed consent patient consent was obtained.

## Discussion

Amyloidosis is a rare disease caused by the accumulation of amorphous proteins in the extracellular space. It is classified as localized amyloidosis when it occurs in a single organ and as systemic amyloidosis when it occurs in multiple organs. Primary amyloidosis is caused by immune cell disorders, such as multiple myeloma and other immune cell anomalies (1). Secondary amyloidosis is a reactive condition caused by diseases leading to chronic inflammation and tissue destruction (3). While amyloidosis can accumulate anywhere in the urinary system, the bladder and kidney are the most commonly affected organs (4).

**Correspondence:** Can Sinirsiz MD, Dokuz Eylül University Faculty of Medicine, Department of Urology, İzmir, Türkiye


**E-mail:** cansinirsiz17@gmail.com **ORCID-ID:** orcid.org/0000-0001-8237-7968

**Received:** 27.04.2024 **Accepted:** 29.07.2024 **Epub:** 18.04.2025

**Cite this article as:** Sinirsiz C, Şen V, Tuna EB, Bozkurt O. Primary bladder amyloidosis mimicking bladder cancer: a rare case report. J Urol Surg. [Epub Ahead of Print]


©Copyright 2025 The Author. Published by Galenos Publishing House on behalf of the Society of Urological Surgery.  
This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.





**Figure 1.** A nodular lesion in the lateral side of the left ureter orifice of the bladder (A. CT transverse section, B. Endoscopic images of nodular lesions in the bladder)

CT: Computed tomography



**Figure 2.** The histopathological staining of patient. A. Extracellular eosinophilic, amorphous, and homogeneous amyloid deposits with hematoxylin-eosin. B. Amyloid in Congo red appears orange-red when viewed under a transmitted-light microscope

Patients with bladder amyloidosis often present with common complaints, such as macroscopic painless hematuria (>80% of the patients), irritative urinary symptoms, and symptoms similar to cystitis (5). Ultrasonography and CT urography may detect mass lesions, filling defects, and wall thickening, which may mimic bladder malignancy (2,6). The lesion may appear polypoid or nodular during cystoscopy. Due to the similarity of symptoms and imaging findings to bladder malignancy, cystoscopy should be performed, and histopathological differential diagnosis should be made using TUR or biopsy (2). The diagnosis of amyloidosis

is made by Congo red immunostaining, which gives an apple green reflection under polarized light (3). AL amyloidosis is the most common type encountered in bladder amyloidosis, but AA, ATTR and other types of amyloidosis can also be observed. Patients should also be evaluated for systemic amyloidosis. TUR is the first diagnostic and treatment method for primary bladder amyloidosis (7). In untreated cases, lesion's dimensional progression and obstructive uropathy can be detected during follow-up. Postoperative adjuvant treatment with colchicine and intravesical dimethylsulfoxide (DMSO) has been tried in many cases to prevent recurrence. Patients with diffuse multifocal bladder amyloidosis who could not be completely resected through TUR. The addition of colchicine may improve outcomes by mitigating local inflammation and leading to regression of the lesions. Moreover, intravesical treatment with DMSO every week or every 2 weeks for 3-6 months may dissolve insoluble amyloid fibrils and lead to symptom remission (8).

Patients with diffuse multifocal bladder amyloidosis who experience clinically insignificant improvement in symptoms may benefit from these treatments. Partial or total cystectomy may be required in some cases of bladder amyloidosis (9). For patients who are refractory to all treatments, cystectomy may be an option. Due to the high recurrence rate and diffuse involvement, periodic cystoscopy follow-up is required. Cystoscopy is recommended at 3 months after the first TUR and annually thereafter for the first and second years. In addition, cystoscopic evaluation should be performed if there is hematuria, irritative lower urinary symptoms, or symptoms similar to cystitis, which may indicate recurrence. There are cases of *de novo* urothelial carcinoma with localized amyloidosis (8). However, the optimal treatment and follow-up strategies for primary bladder amyloidosis are not clear in the literature (8). Progression of systemic amyloidosis in patients diagnosed with localized amyloidosis was 1% in all cases. Although rare, this condition must also be followed up from this perspective (8).

## Conclusion

Primary bladder amyloidosis is a rare disease that clinically and radiologically mimics bladder malignancy. A definitive diagnosis should be made through histopathological examination. Patients should be referred for further evaluation of the possibility of systemic amyloidosis. Although it is a benign lesion, there is a risk of obstruction, recurrence, and de novo urothelial carcinoma. Therefore, follow-up should include interval cystoscopy and, if necessary, TUR.

## Ethics

**Informed Consent:** Patient consent was obtained.

## Footnotes

### Authorship Contributions

Surgical and Medical Practices: C.S., V.Ş., E.B.T., O.B., Concept: C.S., V.Ş., E.B.T., O.B., Design: C.S., V.Ş., E.B.T., O.B., Data Collection or Processing: C.S., V.Ş., E.B.T., O.B., Analysis or Interpretation: C.S., V.Ş., E.B.T., O.B., Literature Search: C.S., V.Ş., E.B.T., O.B., Writing: C.S., V.Ş., E.B.T., O.B.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

## References

1. Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. *JAMA*. 2020;324:79–89. [\[Crossref\]](#)
2. Patel P, Pourmandi M, Lombard JS. Primary amyloidosis of the bladder mimicking probable malignancy: a case report. *Urol Case Rep*. 2019;26:100944. [\[Crossref\]](#)
3. Mayor N, Coppola ASJ, Knights H, Nazar T, Hunter H, Mostafid H. Localised amyloidosis of the bladder: a rare mimic of urinary tract malignancy (case report and literature review). *Int J Surg Case Rep*. 2020;77:708–710. [\[Crossref\]](#)
4. Al-Obaidy KI, Grignon DJ. Primary amyloidosis of the genitourinary tract. *Arch Pathol Lab Med*. 2021;145:699–703. [\[Crossref\]](#)
5. Yu ZY, Yan L, Wang HK, Hang G, Wang YY, Wen Q, Chen B. Bladder triangle amyloidosis: a case report and literature review. *Medicine (Baltimore)*. 2022;101:e32179. [\[Crossref\]](#)
6. Chuang E, Hori AM, Hesketh CD, Shorter J. Amyloid assembly and disassembly. *J Cell Sci*. 2018;131:jcs189928. [\[Crossref\]](#)
7. Monge M, Chauveau D, Cordonnier C, Noël LH, Presne C, Makdassi R, Jauréguy M, Lecaque C, Renou M, Grünfeld JP, Choukroun G. Localized amyloidosis of the genitourinary tract: report of 5 new cases and review of the literature. *Medicine (Baltimore)*. 2011;90:212–222. [\[Crossref\]](#)
8. Pyrgidis N, Mykoniatis I, Pegios VF, Sokolakis I, Hatzichristodoulou G, Bourdoumis A, Vakalopoulos I, Sountoulides P. Amyloidosis of the urinary bladder: a systematic review and a proposed management algorithm. *Urology*. 2021;156:e12–e19. [\[Crossref\]](#)
9. Chan ES, Ng CF, Chui KL, Hou SM, Yip SK. Primary bladder amyloidosis—case report of a patient with delayed upper urinary tract obstruction 3 years after the diagnosis. *Amyloid*. 2010;17:36–38. [\[Crossref\]](#)